Soluble interleukin-18 receptor complex is a novel biomarker in rheumatoid arthritis

Arthritis Research and Therapy

Volumn 13, Issue 2, 2011, Pages

  Takei, Satoko ^a   Hoshino, Tomoaki ^a   Matsunaga, Kazuko ^a   Sakazaki, Yuki ^a   Sawada, Masanori ^a   Oda, Hanako ^a   Takenaka, Shin Ichi ^a   Imaoka, Haruki ^a   Kinoshita, Takashi ^a   Honda, Seiyo ^a   Ida, Hiroaki ^a   Fukuda, Taka Aki ^a   Aizawa, Hisamichi ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC CITRULLINATED PEPTIDE ANTIBODY; ETANERCEPT; GAMMA INTERFERON; IMMUNOGLOBULIN M; INTERLEUKIN 13; INTERLEUKIN 18; INTERLEUKIN 18 ANTIBODY; INTERLEUKIN 18 RECEPTOR ALPHA; INTERLEUKIN 18 RECEPTOR BETA; METHOTREXATE; MONOCLONAL ANTIBODY; PEPTIDE; PREDNISOLONE; RHEUMATOID FACTOR; BIOLOGICAL MARKER; INTERLEUKIN 18 RECEPTOR;

ADULT; ADULT ONSET STILL DISEASE; AGED; ANTIBODY AFFINITY; ARTICLE; CELL LINE; CELL SURFACE; CONTROLLED STUDY; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; NATURAL KILLER CELL; OSTEOARTHRITIS; PROTEIN BLOOD LEVEL; PROTEIN ISOLATION; PROTEIN PURIFICATION; RECEIVER OPERATING CHARACTERISTIC; RHEUMATOID ARTHRITIS; SERUM; SYSTEMIC LUPUS ERYTHEMATOSUS; WESTERN BLOTTING; AREA UNDER THE CURVE; BLOOD; METABOLISM; MIDDLE AGED; SENSITIVITY AND SPECIFICITY; SOLUBILITY;

AGED; AREA UNDER CURVE; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; BLOTTING, WESTERN; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; RECEPTORS, INTERLEUKIN-18; ROC CURVE; SENSITIVITY AND SPECIFICITY; SOLUBILITY;

EID: 79953107498     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar3295     Document Type: Article

References (41)

1. Sims JE. IL-1 and IL-18 receptors, and their extended family. Curr Opin Immunol 2002, 14:117-122. 10.1016/S0952-7915(01)00306-5, 11790541.
2. Levine SJ. Mechanisms of soluble cytokine receptor generation. J Immunol 2004, 173:5343-5348.
3. Arend WP, Palmer G, Gabay C. IL-1, IL-18, and IL-33 families of cytokines. Immunol Rev 2008, 223:20-38. 10.1111/j.1600-065X.2008.00624.x, 18613828.
4. Slack J, McMahan CJ, Waugh S, Schooley K, Spriggs MK, Sims JE, Dower SK. Independent binding of interleukin-1α and interleukin-1β to type I and type II interleukin-1 receptors. J Biol Chem 1993, 268:2513-2524.
5. Elzinga BM, Twomey C, Powell JC, Harte F, McCarthy JV. Interleukin-1 receptor type 1 is a substrate for γ-secretase-dependent regulated intramembrane proteolysis. J Biol Chem 2009, 284:1394-1409. 10.1074/jbc.M803108200, 18996842.
6. Hoshino T, Wiltrout RH, Young HA. IL-18 is a potent coinducer of IL-13 in NK and T cells: a new potential role for IL-18 in modulating the immune response. J Immunol 1999, 162:5070-5077.
7. Hoshino T, Yagita H, Ortaldo JR, Wiltrout RH, Young HA. In vivo administration of IL-18 can induce IgE production through Th2 cytokine induction and up-regulation of CD40 ligand (CD154) expression on CD4+ T cells. Eur J Immunol 2000, 30:1998-2006. 10.1002/1521-4141(200007)30:7<1998::AID-IMMU1998>3.0.CO;2-U, 10940889.
8. Dinarello CA. Interleukin-18 and the pathogenesis of inflammatory diseases. Semin Nephrol 2007, 27:98-114. 10.1016/j.semnephrol.2006.09.013, 17336692.
9. Dinarello CA. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol 2009, 27:519-550. 10.1146/annurev.immunol.021908.132612, 19302047.
10. Hoshino T, Kato S, Oka N, Imaoka H, Kinoshita T, Takei S, Kitasato Y, Kawayama T, Imaizumi T, Yamada K, Young HA, Aizawa H. Pulmonary inflammation and emphysema: role of the cytokines IL-18 and IL-13. Am J Respir Crit Care Med 2007, 176:49-62. 10.1164/rccm.200603-316OC, 17400729.
11. Imaoka H, Hoshino T, Takei S, Kinoshita T, Okamoto M, Kawayama T, Kato S, Iwasaki H, Watanabe K, Aizawa H. Interleukin-18 production and pulmonary function in COPD. Eur Respir J 2008, 31:287-297. 10.1183/09031936.00019207, 17989120.
12. Hoshino T, Okamoto M, Sakazaki Y, Kato S, Young HA, Aizawa H. Role of proinflammatory cytokines IL-18 and IL-1β in bleomycin-induced lung injury in humans and mice. Am J Respir Cell Mol Biol 2009, 41:661-670. 10.1165/rcmb.2008-0182OC, 19265174.
13. Torigoe K, Ushio S, Okura T, Kobayashi S, Taniai M, Kunikata T, Murakami T, Sanou O, Kojima H, Fujii M, Ohta T, Ikeda M, Ikegami H, Kurimoto M. Purification and characterization of the human interleukin-18 receptor. J Biol Chem 1997, 272:25737-25742. 10.1074/jbc.272.41.25737, 9325300.
14. Hoshino K, Tsutsui H, Kawai T, Takeda K, Nakanishi K, Takeda Y, Akira S. Cutting edge: generation of IL-18 receptor-deficient mice: evidence for IL-1 receptor-related protein as an essential IL-18 binding receptor. J Immunol 1999, 162:5041-5044.
15. Cheung H, Chen NJ, Cao Z, Ono N, Ohashi PS, Yeh WC. Accessory protein-like is essential for IL-18-mediated signaling. J Immunol 2005, 174:5351-5357.
16. Novick D, Kim SH, Fantuzzi G, Reznikov LL, Dinarello CA, Rubinstein M. Interleukin-18 binding protein: a novel modulator of the Th1 cytokine response. Immunity 1999, 10:127-136. 10.1016/S1074-7613(00)80013-8, 10023777.
17. Hayakawa H, Hayakawa M, Kume A, Tominaga S. Soluble ST2 blocks interleukin-33 signaling in allergic airway inflammation. J Biol Chem 2007, 282:26369-26380. 10.1074/jbc.M704916200, 17623648.
18. Kawashima M, Yamamura M, Taniai M, Yamauchi H, Tanimoto T, Kurimoto M, Miyawaki S, Amano T, Takeuchi T, Makino H. Levels of interleukin-18 and its binding inhibitors in the blood circulation of patients with adult-onset Still's disease. Arthritis Rheum 2001, 44:550-560. 10.1002/1529-0131(200103)44:3<550::AID-ANR103>3.0.CO;2-5, 11263769.
19. Dai SM, Shan ZZ, Xu H, Nishioka K. Cellular targets of interleukin-18 in rheumatoid arthritis. Ann Rheum Dis 2007, 66:1411-1418. 10.1136/ard.2006.067793, 2111635, 17502360.
20. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, Medsger TA, Mitchell DM, Neustadt DH, Pinals RS, Schaller JG, Sharp JT, Wilder RL, Hunder GG. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988, 31:315-324. 10.1002/art.1780310302, 3358796.
21. Steinbrocker O, Traeger CH, Batterman RC. Therapeutic criteria in rheumatoid arthritis. J Am Med Assoc 1949, 140:659-662.
22. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995, 38:44-48. 10.1002/art.1780380107, 7818570.
23. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980, 23:137-145. 10.1002/art.1780230202, 7362664.
24. Hoshino T, Ohta A, Yang D, Kawamoto M, Kikuchi M, Inoue Y, Kamizono S, Ota T, Itoh K, Oizumi K. Elevated serum interleukin 6, interferon-γ, and tumor necrosis factor-α levels in patients with adult Still's disease. J Rheumatol 1998, 25:396-398.
25. Yamaguchi M, Ohta A, Tsunematsu T, Kasukawa R, Mizushima Y, Kashiwagi H, Kashiwazaki S, Tanimoto K, Matsumoto Y, Ota T, et al. Preliminary criteria for classification of adult Still's disease. J Rheumatol 1992, 19:424-430.
26. Altman R, Asch E, Bloch D, Bole G, Borenstein D, Brandt K, Christy W, Cooke TD, Greenwald R, Hochberg M, Howell D, Kaplan D, Koopman W, Longley S III, Mankin H, McShane DJ, Medsger T, Meenan R, Mikkelsen W, Moskowtiz R, Murphy W, Rothschild B, Segal M, Sokoloff L, Wolfe L. Development of criteria for the classification and reporting of osteoarthritis: classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis Rheum 1986, 29:1039-1049. 10.1002/art.1780290816, 3741515.
27. Heinlen LD, McClain MT, Merrill J, Akbarali YW, Edgerton CC, Harley JB, James JA. Clinical criteria for systemic lupus erythematosus precede diagnosis, and associated autoantibodies are present before clinical symptoms. Arthritis Rheum 2007, 56:2344-2351. 10.1002/art.22665, 17599763.
28. Koizumi H, Sato-Matsumura KC, Nakamura H, Shida K, Kikkawa S, Matsumoto M, Toyoshima K, Seya T. Distribution of IL-18 and IL-18 receptor in human skin: various forms of IL-18 are produced in keratinocytes. Arch Dermatol Res 2001, 293:325-333. 10.1007/s004030100237, 11550805.
29. Lee SJ, Cho YS, Cho MC, Shim JH, Lee KA, Ko KK, Choe YK, Park SN, Hoshino T, Kim S, Dinarello CA, Yoon DY. Both E6 and E7 oncoproteins of human papillomavirus 16 inhibit IL-18-induced IFN-γ production in human peripheral blood mononuclear and NK cells. J Immunol 2001, 167:497-504.
30. Kitasato Y, Hoshino T, Okamoto M, Kato S, Koda Y, Nagata N, Kinoshita M, Koga H, Yoon DY, Asao H, Ohmoto H, Koga T, Rikimaru T, Aizawa H. Enhanced expression of interleukin-18 and its receptor in idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol 2004, 31:619-625. 10.1165/rcmb.2003-0306OC, 15308504.
31. Hoshino T, Yamada A, Honda J, Imai Y, Nakao M, Inoue M, Sagawa K, Yokoyama MM, Oizumi K, Itoh K. Tissue-specific distribution and age-dependent increase of human CD11b+ T cells. J Immunol 1993, 151:2237-2246.
32. Hoshino T, Kawase Y, Okamoto M, Yokota K, Yoshino K, Yamamura K, Miyazaki J, Young HA, Oizumi K. Cutting edge: IL-18-transgenic mice: in vivo evidence of a broad role for IL-18 in modulating immune function. J Immunol 2001, 166:7014-7018.
33. Toda R, Hoshino T, Kawayama T, Imaoka H, Sakazaki Y, Tsuda T, Takada S, Kinoshita M, Iwanaga T, Aizawa H. Validation of "lung age" measured by spirometry and handy electronic FEV1/FEV6 meter in pulmonary diseases. Intern Med 2009, 48:513-521. 10.2169/internalmedicine.48.1781, 19336952.
34. Okamura H, Tsutsi H, Komatsu T, Yutsudo M, Hakura A, Tanimoto T, Torigoe K, Okura T, Nukada Y, Hattori K, Akita K, Namba M, Tanabe F, Konishi K, Fukuda S, Kurimoto M. Cloning of a new cytokine that induces IFN-γ production by T cells. Nature 1995, 378:88-91. 10.1038/378088a0, 7477296.
35. Kim SH, Reznikov LL, Stuyt RJ, Selzman CH, Fantuzzi G, Hoshino T, Young HA, Dinarello CA. Functional reconstitution and regulation of IL-18 activity by the IL-18Rβ chain. J Immunol 2001, 166:148-154.
36. Levine SJ. Molecular mechanisms of soluble cytokine receptor generation. J Biol Chem 2008, 283:14177-14181. 10.1074/jbc.R700052200, 2386928, 18385130.
37. Reddy P, Slack JL, Davis R, Cerretti DP, Kozlosky CJ, Blanton RA, Shows D, Peschon JJ, Black RA. Functional analysis of the domain structure of tumor necrosis factor-α converting enzyme. J Biol Chem 2000, 275:14608-14614. 10.1074/jbc.275.19.14608, 10799547.
38. Smith DE, Hanna R, Della F, Moore H, Chen H, Farese AM, MacVittie TJ, Virca GD, Sims JE. The soluble form of IL-1 receptor accessory protein enhances the ability of soluble type II IL-1 receptor to inhibit IL-1 action. Immunity 2003, 18:87-96. 10.1016/S1074-7613(02)00514-9, 12530978.
39. Veenbergen S, Smeets RL, Bennink MB, Arntz OJ, Joosten LA, van den Berg WB, van de Loo FA. The natural soluble form of IL-18 receptor β exacerbates collagen-induced arthritis via modulation of T-cell immune responses. Ann Rheum Dis 2010, 69:276-283. 10.1136/ard.2008.100867, 19188194.
40. Andre R, Wheeler RD, Collins PD, Luheshi GN, Pickering-Brown S, Kimber I, Rothwell NJ, Pinteaux E. Identification of a truncated IL-18Rβ mRNA: a putative regulator of IL-18 expressed in rat brain. J Neuroimmunol 2003, 145:40-45. 10.1016/j.jneuroim.2003.09.005, 14644029.
41. Stabler T, Piette JC, Chevalier X, Marini-Portugal A, Kraus VB. Serum cytokine profiles in relapsing polychondritis suggest monocyte/macrophage activation. Arthritis Rheum 2004, 50:3663-3667. 10.1002/art.20613, 15529362.